Vaccine Therapy in Treating Patients With HER2-Negative Stage III-IV Breast Cancer

Inclusion Criteria:

* Patients with stage III-IV HER2 negative breast cancer treated with primary or salvage therapy and now have:

  * No evidence of disease (NED), or
  * Stable bone only disease
* Patients who have completed standard of care and recovered with mild to no residual toxicity from recent therapy
* Patients must be at least 28 days post cytotoxic chemotherapy, and/or monoclonal antibody therapy (excluding bone-directed therapy), prior to enrollment
* Patients must be at least 28 days post systemic steroids prior to enrollment
* Patients on bisphosphonates, denosumab, and/or endocrine therapy are eligible
* Patients must have Eastern Cooperative Oncology Group (ECOG) performance status score of =\< 1
* Patients must have recovered from major infections and/or surgical procedures, and in the opinion of the investigator, not have any significant active concurrent medical illnesses precluding protocol treatment
* Estimated life expectancy of more than 6 months
* White blood cells (WBC) \>= 3000/mm\^3 (within 30 days of first vaccination)
* Lymphocyte count \>= 800/mm\^3 (within 30 days of first vaccination)
* Platelet count \>= 75,000/mm\^3 (within 30 days of first vaccination)
* Hemoglobin (Hgb) \>= 10 g/dl (within 30 days of first vaccination)
* Serum creatinine \<= 1.2 mg/dl or creatinine clearance \> 60 ml/min (within 30 days of first vaccination)
* Total bilirubin \<= 1.5 mg/dl (within 30 days of first vaccination)
* Aspartate aminotransferase (AST)/serum glutamic oxaloacetic transaminase (SGOT) \<= 2 times upper limit of normal (ULN) (within 30 days of first vaccination)
* Blood glucose \< 1.5 ULN (within 30 days of first vaccination)
* All patients who are having sex that can lead to pregnancy must agree to contraception for the duration of study

Exclusion Criteria:

* Patients with any of the following cardiac conditions:

  * Symptomatic restrictive cardiomyopathy
  * Unstable angina within 4 months prior to enrollment
  * New York Heart Association functional class III-IV heart failure on active treatment
  * Symptomatic pericardial effusion
* Patients at risk for gastrointestinal bleeding (example: peptic ulcer disease, prolonged daily non-steroidal anti-inflammatory use)
* Patients with any seizure disorder
* Patients with any contraindication to receiving rhuGM-CSF based products
* Patients with any clinically significant autoimmune disease uncontrolled with treatment
* Patients who are simultaneously enrolled in any other treatment study
* Patients who are pregnant or breastfeeding